Sean S. Keating

This study identifies a transient protein folding response in early TDP-43 disease that reduces aggregation, with DNAJB5 as a protective factor, and shows proteomic similarities between mouse and human TDP-43 proteinopathies.

This study investigates how RNA-binding deficiency and post-translational modifications of TDP-43 lead to its sequestration and depletion, contributing to neurodegeneration in ALS and FTD.

This study shows riluzole does not improve disease outcomes in a mouse model of ALS with cytoplasmic TDP-43 pathology.